Zanidatamab plus tislelizumab for HER2-positive stomach and bowel cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two medications (zanidatamab and tislelizumab) for people with HER2-positive gastrointestinal cancers. It aims to see if this treatment can shrink tumors or prevent recurrence in early-stage cancers, and provide a new option for advanced colorectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have gastric (stomach) cancer, gastroesophageal junction cancer, or colorectal cancer that is HER2-positive (a specific protein on your tumor cells).
- You must be between 18 and 75 years old.
- You should be in reasonably good health, able to perform daily activities (ECOG score 0 or 1).
- Your tumor type must meet specific criteria, such as being early-stage (localized) for rectal or gastric cancer, or advanced and having failed at least one prior treatment for colorectal cancer.
- You must have normal organ function, including good kidney, liver, and blood counts.
- You cannot have untreated hepatitis B or C, active HIV, or certain other infections or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted drug (zanidatamab, which attacks HER2-positive cancer cells) combined with chemotherapy can shrink stomach cancer before surgery, making it easier to remove. It may also help people whose cancer has spread a bit, by making it operable.
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.
This trial tests a new drug called zanidatamab given together with standard chemotherapy before surgery for a type of stomach or junction cancer that is HER2-positive (has a specific protein). The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This study tests whether adding a new targeted drug called zanidatamab to standard chemotherapy before and after surgery can improve the chances of getting rid of HER2-positive stomach or esophageal cancer. It is designed for patients whose cancer can still be removed with surgery and has not spread.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.